Shenzhen Zero One Life Science and Technology

Shenzhen Zero One Life Science and Technology Co., Ltd. (01Life), established in 2016, is a biotechnology firm centered on the human microbiome. The founding team, including CEO Wang Xiaokai, CTO Xu Xiaoqiang, CDO Xia Yan, and CLO Chen Xi, were classmates at the University of Chinese Academy of Sciences, specializing in bioinformatics and genomics, making them early domestic experts in the gut flora field. COO Liu Qiwei brings operational management experience from a publicly listed company. 01Life focuses on developing new solutions for health, clinical research, and disease treatment by leveraging human micro-ecological technology.

The company's business model is built upon its core technology platform, described as "three libraries and three platforms": a human micro-ecological big database, a live bacteria bank, a metabolite library, a high-throughput screening platform, a bioinformatics platform, and an application development platform. This integrated system facilitates a range of activities from gut microbiome gene detection and big data analysis to the screening and commercial application of new bacterial strains. Revenue generation stems from two main verticals: micro-ecological pharmaceuticals and health consumer products. In the pharmaceutical space, 01Life develops original drug pipelines targeting conditions like atopic dermatitis, with plans to expand into diabetes, metabolic diseases, and mental health. On the consumer side, the company partners with large corporations such as China Resources Jiangzhong and Mengniu Truelove to provide gut health data analysis and co-develop innovative probiotic products for the Chinese market.

01Life offers a portfolio that includes in-vitro diagnostics (IVDs), functional foods, and drug development pipelines. A key consumer-facing product line is the "Yinwei" (因微) series, which offers at-home fecal sampling kits. Utilizing metagenomic sequencing technology, these kits provide users with a detailed analysis of their gut microbiome, followed by personalized recommendations for the Yinwei series of probiotics. The firm has also developed pipelines for live biotherapeutics and small molecule drugs aimed at skin issues like atopic dermatitis, acne, and hair loss. To date, 01Life has launched seven original new drug pipelines, five genetic testing products, and six "probiotic+" products, and has established research collaborations with over 100 medical institutions.

Keywords: microbiome, biotechnology, gut flora, micro-ecological, probiotics, genetic testing, drug discovery, clinical research, bioinformatics, data-driven health, atopic dermatitis, metabolic diseases, live biotherapeutics, small molecule drugs, functional foods, personalized nutrition, Shenzhen, Wang Xiaokai, human micro-ecology, bacterial strain screening